Discover United Therapeutics' Q1 2025 earnings insights: record revenues, growth strategies, and pipeline advancements.

FDA can grant final approval of YUTREPIA after blocking regulatory exclusivity expires on May 23, 2025 ...

The results exceeded Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $6.29 per share. The drugmaker posted revenue of $794.4 ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. United Therapeutics met analysts’ revenue expectations last ...

Good morning and welcome to the United Therapeutics Corporation First Quarter 2025 Corporate Update. My name is Dorwin [ph] and I will be your conference operator today. All participants on the ...

United Therapeutics Corporation (UTHR) reported its first-quarter 2025 earnings, showcasing a strong financial performance that exceeded market expectations. The company posted an earnings per ...

Biotechnology company United Therapeutics (NASDAQ:UTHR) reported Q1 CY2025 results , with sales up 17.2% year on year to $794 ...

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $352.0, a high estimate of $425.00, and a low estimate of $314.00. This current average represents a 5.57% ...